TD Cowen lowered the firm’s price target on BeiGene to $222 from $304 and keeps an Outperform rating on the shares. The firm said in conjunction with their Q3 earnings preview they are updating their model to account for anticipated negative impacts from Chinese anti-corruption efforts in Q3 and Q4 and long-term uncertainties surrounding the Chinese market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BGNE:
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- BeiGene says Phase 3 RATIONALE 305 trial data show improved overall survival
- BeiGene says Phase 3 RATIONALE 315 trial met primary endpoints
- Cellectar Biosciences appoints Yoon, Nanduri as VPs
- BeiGene reports positive CHMP opinion for Brukinsa